Abstract | PURPOSE: MATERIALS AND METHODS: A total of 58 patients (73 lesions) were treated from 2004 to 2016. Patients were candidates for analysis if a maximum of 3 metastases were diagnosed and the primary tumor was resected. Toxicity was classified according to Common Terminology Criteria for Adverse Events version 3. RESULTS: All patients had renal cell carcinoma, in particular the clear cell type in 82.7%. A total of 39 metastases (53.4%) were located in the lungs and 19 (26%) were in the lymph nodes. Less common were metastases to bone (9.5% of cases), the liver (4.1%) and the adrenal gland (6.8%). Median followup was 16.1 months (range 3.5 to 157.1). The local control rate at 12 and 18 months was 90.2% and 90.2%, respectively. The progression-free survival rate at 12 and 18 months was 46.2% (95% CI 32.2-59) and 35% (95% CI 21.4-48.9), respectively. On univariate and multivariable analyses metachronous and single metastases predicted better progression-free survival. Systemic therapy before stereotactic body radiation therapy predicted improved local control in clear cell cases. CONCLUSIONS: Stereotactic body radiation therapy can be considered a safe approach and it provides effective local control of oligometastatic renal cell carcinoma. However, future prospective studies are necessary to evaluate the impact on survival and quality of life.
|
Authors | Ciro Franzese, Davide Franceschini, Lucia Di Brina, Giuseppe Roberto D'Agostino, Pierina Navarria, Tiziana Comito, Pietro Mancosu, Stefano Tomatis, Marta Scorsetti |
Journal | The Journal of urology
(J Urol)
Vol. 201
Issue 1
Pg. 70-76
(01 2019)
ISSN: 1527-3792 [Electronic] United States |
PMID | 30179619
(Publication Type: Journal Article)
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Carcinoma, Renal Cell
(mortality, radiotherapy, secondary)
- Humans
- Kidney Neoplasms
(mortality, pathology, therapy)
- Middle Aged
- Nephrectomy
- Progression-Free Survival
- Radiosurgery
- Retrospective Studies
- Survival Rate
- Treatment Outcome
- Whole-Body Irradiation
|